Skip to main content
. 2022 Oct 26;11(21):6320. doi: 10.3390/jcm11216320

Table 3.

Two-way mixed analysis of variance results for the logarithm of dose-adjusted tacrolimus trough concentrations.

LogC0/D n Month 6 Month 9 Month 12 Total Means 95% CI a
CYP3A5 expressers 110 0.03 ± 0.18 0.04 ± 0.17 0.05 ± 0.17 0.04 b 0.01, 0.07
CYP3A5 nonexpressers 78 0.32 ± 0.18 0.34 ± 0.17 0.36 ± 0.19 0.34 b 0.30, 0.38
Total means - 0.18 c 0.19 0.20 c - -
95% CI a - 0.15, 0.20 0.17, 0.22 0.18, 0.23 - -
Source Sum of Squares Mean square df F p-Value Partial eta-squared
CYP3A5*3 polymorphisms 12.2 12.2 1, 186 158 <0.001 0.459
Time 0.072 0.039 1.85, 345 4.02 0.021 0.021
Polymorphisms × Time 0.005 0.003 1.85, 345 0.279 0.740 0.001

LogC0/D, logarithms of dose-adjusted trough concentrations of tacrolimus in ng/mL per mg/day. a 95% confidence interval of total means. b p < 0.001 for comparison between CYP3A5 expressers and nonexpressers. c p < 0.05 for comparison between month 6 and month 12 (Bonferroni correction).